PLANTATION, Fla., Oct. 10, 2005 (PRIMEZONE) -- MEDirect Latino Inc. (Pink Sheets:MLTO) (www.medirectlatino.org), the first national provider of direct-to-consumer Medicare reimbursed medical products focused exclusively on chronic diseases afflicting the Hispanic community, today announced record operating results for September, 2005 in gross billings, new patient shipments, call volume and average opening orders. MEDirect Latino reports gross billings of $304,621 during the month, a 109% increase over August billings of $145,984, while maintaining gross product profit margins of 74% during the period. During the month, the Company's media campaign produced qualified patient intake call volume of 3,772 calls, an increase of 93% over August. Total patient orders for September numbered 3,108, which included 1,304 new patient shipments, and an additional 1,804 patients approved, but pending shipment for regulatory processing. MEDirect Latino expects to monetize its approved/on-hold patients in October, which is typical for the industry model. The Company's closing ratio during August was 82% of the total qualified responses received from the media campaign. New patient shipments in September increased 104% over new patient shipments in August.
Mr. Raymond Talarico, Co-Chairman and CEO of MEDirect Latino, in discussing the Company's September results stated: "Our revenue increases prove the viability of the Hispanic Medicare market for our products and services and the fact that our media campaign, with increasing effectiveness, is reaching our targeted customer. Our proprietary research and marketing program, which was developed and is being implemented by Company COO Mr. Charles Hansen, is one of the cornerstones of the success of our business, and continues to prove itself in Puerto Rico while our domestic campaign, which launched nationally on Telemundo September 20th, has been overwhelmingly successful. As we continue to outperform projections, the Company has stepped up efforts to hire, train and educate new employees on the methods MEDirect employs in the sales, care and service we provide our customers. MEDirect, in the Hispanic community, is quickly becoming recognized as a provider of healthcare products and services that cares about our Latin customers and their families. This is the vision the Company was founded upon, and this vision has become intertwined with our corporate culture."
Senior management will attend Medtrade Conference & Exposition, October 17-20, 2005, at the Georgia World Congress Center, to finalize agreements to distribute additional products to the Company's growing Hispanic Medicare customer database. The Company's product extension goals focus on products which complement its existing line of branded and co-branded diabetic diagnostic testing supplies in the Medicare reimbursable regime, which offer natural extensions and enhance the quality of life of its customers. In addition, the Company will complete discussions with international manufacturers and distributors to initiate commercial distribution of its branded line of culturally specific diabetic care products, into Mexico, Central, and South America.
ANALYTICAL REPORTS
Additional Company information may be obtained by reviewing a detailed research report published by noted micro-cap analyst, Mr. William Ritger, President of The Research Works, Inc. covering MEDirect Latino. The report is now available for review at: http://www.stocksontheweb.com/mlto.pdf.
Additional Company information may be obtained by reviewing a comprehensive analytical profile generated by small cap analyst, Mr. Gerald Kieft, President of Wall Street Resources, Inc. The 27-page report includes detailed information on the Company's business model, products, industry, valuation, management, and risks. The free report is available at: http://www.wallstreetresources.net/pdf/fc/MLTO2.pdf.
ABOUT MEDIRECT LATINO:
MEDirect Latino (Pink Sheets:MLTO) (www.medirectlatino.org) is a rapidly growing, uniquely positioned provider of direct-to-consumer Medicare reimbursed medical products focused exclusively on chronic diseases afflicting the Hispanic community in the United States and Puerto Rico. MEDirect is the only company positioned to serve the U.S. Hispanic healthcare market as a direct-to-consumer Medicare provider on an authentically national level. The Company's current focus is the distribution of products for the treatment of Type II diabetes specifically because of its disproportionate impact and increasing diagnosis rate within the U.S. Hispanic population, noting an incidence of 120% higher than among non-Hispanic whites. Type II diabetes was also targeted because of its unique status within the Medicare reimbursement regime and because of its high degree of correlation to other chronic conditions such as high blood pressure and heart disease. These other conditions represent considerable future market potential that will allow MEDirect to efficiently scale its model by leveraging its existing client base and infrastructure.
The current Hispanic market for MEDirect's products is conservatively estimated at approximately $748 million in the continental United States. The size of the opportunity is understated by such figures as an estimated 1.2 million of the over 4.1 million Hispanics in the United States over 65 eligible to receive Medicare benefits are currently collecting these benefits with an estimate that over 1.4 million of those Medicare-eligible Hispanics have diabetes (implying a potential continental U.S. market for MEDirect products of approximately $1 billion).
Safe Harbor Disclosure:
This press release includes "forward-looking statements" within the meaning of the federal securities laws, commonly identified by such terms as "believes," "looking ahead," "anticipates," "estimates" and other terms with similar meaning. Although the Company believes that the assumptions upon which its forward-looking statements are based are reasonable, it can give no assurance that these assumptions will prove to be correct. Important factors that could cause actual results to differ materially from the Company's projections and expectations are disclosed in the Company's filings with the Securities and Exchange Commission. All forward-looking statements in this press release are expressly qualified by such cautionary statements and by reference to the underlying assumptions.
The MEDirect Latino Inc. logo is available at:http://www.primezone.com/newsroom/prs/?pkgid=1873